The Garbo technology platform is committed to the research in the field of anesthesia perioperative period and the research of injection drug delivery system. It has successively established many research and development platforms, such as Qingyuan Pharmaceutical Microemulsion Delivery System Engineering Technology Research and Development Center, Guangdong Provincial Intravenous Fat Emulsion Engineering Technology Research Center, Guangdong Provincial Postdoctoral Innovation and Practice Base, Guangdong Provincial Enterprise Technology Center, Guangdong Provincial Doctor Workstation and National Postdoctoral Work Station (sub station). It has a research and development team of up to 90 people, and has introduced the Qingyuan intravenous fat emulsion research and innovation team, the core technology and industrialization team of the Yangfan plan lipid drug delivery system, which provides a good foundation for scientific research and innovation.

In recent years, the Garbo technology platform has made great achievements in research and development projects, approved production approvals and patents. In 2012, it was entrusted by the drug regulatory department to draft and formulate the national quality standard for propofol injection. The company's main products "propofol emulsion injection", "propofol medium/long chain fat emulsion injection", "ropivacaine hydrochloride injection" and "methoxamine hydrochloride injection" were identified as high-tech products. The company has successively won the 16th National Patent Excellence Award in China, the first prize of Qingyuan Science and Technology Progress Award, the third prize of Guangdong Provincial Science and Technology Award, the first prize of "Innovation Qingyuan" Science and Technology Award in 2021 and the "May 1 Labor Award" in Guangdong Province in 2021.